NCT04412187 (ICARUS) is a NA clinical trial of [18F]-GE-180 PET in Ischemic Stroke, sponsored by Martin Dichgans.

Who is sponsoring NCT04412187?

NCT04412187 is sponsored by Martin Dichgans.

What drugs are being tested in NCT04412187?

Interventions in NCT04412187: [18F]-GE-180 PET, 3T MRI, immune cell profiling in blood.

What condition does NCT04412187 study?

NCT04412187 studies Ischemic Stroke.

Is NCT04412187 still recruiting?

NCT04412187 is currently recruiting now. Last updated 4 April 2025.

Last reviewed 2025-04-04 · How we verify

NCT04412187: ICARUS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Inflammatory faCtors AfteR acUte Ischemic Stroke

Recruiting now NA Last updated 4 April 2025

What this trial tests

NA trial testing [18F]-GE-180 PET in Ischemic Stroke in 36 participants. Currently enrolling.

Timeline

1 July 2020

Primary endpoint
31 December 2026

31 December 2027

Quick facts

Lead sponsor	Martin Dichgans
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	36
Start date	1 July 2020
Primary completion	31 December 2026
Estimated completion	31 December 2027
Sites	2 locations across Germany

Drugs / interventions tested

[18F]-GE-180 PET
3T MRI
immune cell profiling in blood

Conditions studied

Ischemic Stroke — all drugs for Ischemic Stroke →

Sponsor

Martin Dichgans

Who can join

50 and older, any sex, with Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

ICARUS is an interventional single-centre hospital-based cohort study in patients admitted to the stroke unit with an acute ischemic stroke. The aims of the study are to i) define the characteristics and determinants of microglial activation after human stroke, and ii) assess the correlation of microglial activation with circulating inflammatory markers, structural brain changes on neuroimaging, and neurological outcomes. ICARUS involves serial TSPO-PET imaging along with serial MRI, immune cell profiling in blood, and both clinical and laboratory assessments in 36 patients with acute ischemic stroke caused by a cortical (N=18) or strictly subcortical (N=18) infarct. In a substudy, the investigators will include 10 independently recruited patients with acute ischemic stroke to assess MRI arterial spin labelling (ASL) sequences as a marker for perfusion measurement of the TSPO tracer.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Imaging Inflammation with Positron Emission Tomography.
Iking J, Staniszewska M, Kessler L, Klose JM, et al · · 2021 · cited 37× · PMID 33669804 · DOI 10.3390/biomedicines9020212
Novel PET Imaging of Inflammatory Targets and Cells for the Diagnosis and Monitoring of Giant Cell Arteritis and Polymyalgia Rheumatica.
van der Geest KSM, Sandovici M, Nienhuis PH, Slart RHJA, et al · · 2022 · cited 21× · PMID 35733858 · DOI 10.3389/fmed.2022.902155
Global research hotspots and trends in microglia in ischemic stroke.
Liu Y, Ye Y, Dai F, Bai L, et al · · 2025 · PMID 41280893 · DOI 10.3389/fimmu.2025.1622499

Verify or expand the search:

Other recruiting trials for Ischemic Stroke

Currently open trials in the same condition.

NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
NCT07375953 — Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK) · Phase 2 · recruiting
NCT07375966 — Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours · Phase 2 · recruiting
NCT07491952 — Continuous Dual Aspiration Technique With Zoom System for Stroke · recruiting
NCT07371455 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants · Phase 1 · recruiting

Other Martin Dichgans trials

Trials by the same sponsor.

NCT06128824 — High Frequency Imaging in Cerebral Amyloid Angiopathy · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04412187 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Martin Dichgans
Last refreshed: 4 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04412187.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing